Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group

Dorte Lisbet Nielsen, Karsten D Bjerre, Erik H Jakobsen, Søren Cold, Lars Eric Stenbygaard, Peter G Sørensen, Claus Kamby, Susanne Møller, Charlotte L T Jørgensen, Michael Andersson

27 Citationer (Scopus)

Abstract

The objective of this phase III study was to compare the efficacy of gemcitabine plus docetaxel (GD) versus docetaxel in patients with advanced breast cancer.
OriginalsprogEngelsk
TidsskriftJournal of Clinical Oncology
Vol/bind29
Udgave nummer36
Sider (fra-til)4748-54
Antal sider7
ISSN0732-183X
DOI
StatusUdgivet - dec. 2011

Fingeraftryk

Dyk ned i forskningsemnerne om 'Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group'. Sammen danner de et unikt fingeraftryk.

Citationsformater